CYP2D6*1 is a specific haplotype found on the cytochrome P450 family 2 subfamily D member 6 gene. This haplotype is intricately connected to 53 specific variants. It plays a significant role in how individuals metabolize certain drugs, especially oxycodone, haloperidol, carvedilol, simvastatin, risperidone, gefitinib, ketoprofen, timolol, fentanyl, ondansetron, lovastatin, olanzapine, aripiprazole, mirtazapine. CYP2D6*1 has a Haplotype Performance of 100%. The combined haplotype performances of two haplotypes and individual posseses on cytochrome P450 family 2 subfamily D member 6 determines the overall gene performance. The gene performance indicates the metabolism rate, classifying individuals as either poor, intermediate, extensive, or ultrarapid metabolizers. This has a direct influence on how they process certain drugs.
Role of the Gene that carries the Haplotype CYP2D6*1
The gene cytochrome P450 family 2 subfamily D member 6, plays a crucial role in the way our body processes fat by breaking it down and managing its levels. This occurs mostly in the liver, an essential organ for maintaining healthy body functions. The gene can lead to a change in the protein structure, potentially causing inefficient breakdown of fat. This may contribute to an increased risk of developing liver-related health issues such as fatty liver disease. While genetics play a part, maintaining a healthy lifestyle can help minimize these risks.
CYP2D6*1
% Haplotype Performance:
100%
This is the standard or typical haplotype performance. The haplotype performance is at a "normal" level.
The haplotype performances of two haplotypes an individual possess on cytochrome P450 family 2 subfamily D member 6 determines their overall gene performance.
100% Haplotype Performance
The haplotype performance of a haplotype, when considering drug metabolization, provides a quantifiable measure of how effectively a person's genetics might influence their ability to metabolize or break down specific drugs. The combined effect of the two haplotypes you possess (i.e., the two sets of variants) will determine your overall gene performance related to drug metabolism.
Set of variants that define CYP2D6*1
Haplotypes are linked to multiple variants, and each variant in the haplotype has a specific allele.
there are 53 Variants linked to CYP2D6*1 in the databse:
CYP2D6*1
Variant
Allele
Summary
rs16947
G
rs16947 is a genetic variant on gene CYP2D6.
rs769258
C
rs769258 is a genetic variant on gene CYP2D6.
rs1058164
S
rs1058164 is a genetic variant on gene CYP2D6.
rs1058172
C
rs1058172 is a genetic variant on gene CYP2D6.
rs1065852
G
rs1065852 is a genetic variant on gene CYP2D6.
rs1135822
A
rs1135822 is a genetic variant on gene CYP2D6.
rs1135824
T
rs1135824 is a genetic variant on gene CYP2D6.
rs1135828
A
rs1135828 is a genetic variant on gene CYP2D6.
rs1135840
C
rs1135840 is a genetic variant on gene CYP2D6.
rs3892097
C
rs3892097 is a genetic variant.
rs5030655
A
rs5030655 is a genetic variant.
rs5030656
TCT
rs5030656 is a genetic variant.
rs5030862
C
rs5030862 is a genetic variant on gene CYP2D6.
rs5030865
C
rs5030865 is a genetic variant on gene CYP2D6.
rs5030867
T
rs5030867 is a genetic variant on gene CYP2D6.
rs17002853
A
rs17002853 is a genetic variant on gene CYP2D6.
rs28371696
C
rs28371696 is a genetic variant on gene CYP2D6.
rs28371703
G
rs28371703 is a genetic variant on gene CYP2D6.
rs28371704
T
rs28371704 is a genetic variant on gene CYP2D6.
rs28371706
G
rs28371706 is a genetic variant on gene CYP2D6.
rs28371710
C
rs28371710 is a genetic variant on gene CYP2D6.
rs28371717
C
rs28371717 is a genetic variant on gene CYP2D6.
rs28371725
C
rs28371725 is a genetic variant.
rs35742686
T
rs35742686 is a genetic variant.
rs59421388
C
rs59421388 is a genetic variant on gene CYP2D6.
rs61736512
C
rs61736512 is a genetic variant on gene CYP2D6.
rs61736517
T
rs61736517 is a genetic variant on gene CYP2D6.
rs61745683
C
rs61745683 is a genetic variant on gene CYP2D6.
rs72549346
AC
rs72549346 is a genetic variant.
rs72549347
G
rs72549347 is a genetic variant on gene CYP2D6.
rs72549349
C
rs72549349 is a genetic variant.
rs72549351
TCAG(2)
rs72549351 is a genetic variant.
rs72549352
G
rs72549352 is a genetic variant.
rs72549353
TTAG
rs72549353 is a genetic variant.
rs72549354
C
rs72549354 is a genetic variant.
rs72549356
AAAGGGGCG
rs72549356 is a genetic variant.
rs72549358
C
rs72549358 is a genetic variant on gene CYP2D6.
rs77913725
C
rs77913725 is a genetic variant on gene CYP2D6.
rs78482768
G
rs78482768 is a genetic variant on gene CYP2D6.
rs118203758
C
rs118203758 is a genetic variant on gene CYP2D6.
rs201377835
C
rs201377835 is a genetic variant.
rs267608295
G
rs267608295 is a genetic variant on gene CYP2D6.
rs267608297
G
rs267608297 is a genetic variant on gene CYP2D6.
rs267608302
T
rs267608302 is a genetic variant on gene CYP2D6.
rs267608308
C
rs267608308 is a genetic variant on gene CYP2D6.
rs267608309
G
rs267608309 is a genetic variant on gene CYP2D6.
rs267608310
G
rs267608310 is a genetic variant on gene CYP2D6.
rs267608313
G
rs267608313 is a genetic variant on gene CYP2D6.
rs267608319
C
rs267608319 is a genetic variant on gene CYP2D6.
rs375135093
A
rs375135093 is a genetic variant on gene CYP2D6.
rs730882170
CACATCCGGATGTAGGATC
rs730882170 is a genetic variant.
rs730882251
G
rs730882251 is a genetic variant on gene CYP2D6.
rs774671100
A
rs774671100 is a genetic variant.
CYP2D6*1
Did you know that haplotypes play a major role in pharmacogenetics?
Certain haplotypes in combination can influence how a person's body metabolizes drugs. This is because these haplotypes can affect the function of enzymes responsible for drug metabolism. A change or variation in the DNA sequence of a gene that codes for a drug-metabolizing enzyme can increase or decrease the activity of that enzyme.
Based on the activity of these enzymes (influenced by haplotypes), individuals can be classified into different metabolizer categories:
- Poor Metabolizers (PMs): These individuals have little or no enzyme activity due to certain genetic variations. As a result, they might not metabolize certain drugs efficiently, leading to a higher risk of side effects because the drug remains in their system for a longer time.
- Intermediate Metabolizers (IMs): These people have reduced enzyme activity. They metabolize drugs slower than normal metabolizers but faster than poor metabolizers.
- Extensive Metabolizers (EMs): This is the "standard" or "expected" rate of metabolization. Drugs are metabolized at a regular rate, leading to expected drug efficacy and side effects.
- Ultrarapid Metabolizers (UMs): These individuals have increased enzyme activity. They break down certain drugs very quickly, which can decrease the effectiveness of the drug because it's cleared from their system too rapidly.
In conclusion, understanding one's haplotype and consequent metabolizer status can be crucial for personalized medicine. It can provide guidance on drug selection and dosing to optimize therapeutic outcomes and minimize adverse reactions.
Pharmacogenetics
The CYP2D6*1 haplotype is linked to the CYP2D6 gene, a key component in the body's drug-processing system. This gene provides the blueprint for an enzyme pivotal in breaking down a range of medicines. The presence of the CYP2D6*1 haplotype can influence the efficiency of this enzyme. Based on its activity score, individuals with this haplotype might be classified as poor, intermediate, normal, or ultrarapid metabolizers. This classification is vital as it dictates how rapidly one processes certain medications, potentially impacting the drug's efficacy and risk of side effects. Recognizing the presence of CYP2D6*1 in an individual can guide healthcare professionals in tailoring medication doses to achieve optimal therapeutic outcomes.
there are 17 Drugs associated with 17 Variants that are located on CYP2D6